GlassScriptPhysician profile
Leslie S Jones
NPI 1982070942
$1,998.05
in general payments reported to CMS, 2019-2025
23 companies · $13.48 in 2025
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $175 · 2022: $349 · 2023: $623 · 2024: $838 · 2025: $13.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,473.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $490.84 | 2021-2024 | |
| Novo Nordisk INC | $248.31 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $140.28 | 2022-2024 | Zepbound, Mounjaro, Jardiance |
| Otsuka America Pharmaceutical, INC. | $135.30 | 2022-2023 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $122.07 | 2022-2024 | Vivitrol, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $119.67 | 2021-2024 | Caplyta |
| Corium, LLC | $97.18 | 2023-2024 | Azstarys |
| Axsome Therapeutics, INC. | $84.82 | 2023-2024 | Auvelity |
| Lundbeck LLC | $81.69 | 2022-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $64.62 | 2022-2024 | Trintellix |
| Exact Sciences Corporation | $52.20 | 2023-2024 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $49.68 | 2021 | |
| Janssen Pharmaceuticals, INC | $47.15 | 2021-2024 | Invega Sustenna |
| Amgen INC. | $46.80 | 2024 | Repatha |
| Tris Pharma INC | $42.85 | 2023-2024 | Dyanavel Xr |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $35.52 | 2023 | |
| Idorsia Pharmaceuticals US INC | $29.44 | 2023 | Quviviq |
| Mylan Specialty L.P. | $22.68 | 2023 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $22.47 | 2023 | Austedo Xr |
| Sumitomo Pharma America, INC. | $18.36 | 2024 | Gemtesa |
| Dexcom, INC. | $17.60 | 2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $15.90 | 2022 | |
| Avanir Pharmaceuticals, INC. | $12.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.